Atea Pharmaceuticals (AVIR) Share-based Compensation (2019 - 2026)

Atea Pharmaceuticals' Share-based Compensation history runs 8 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 46.35% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $17.5 million (down 62.07% YoY), while the FY2025 annual figure was $20.7 million, down 59.97% from the prior year.
• Share-based Compensation was $3.7 million for Q1 2026 at Atea Pharmaceuticals, down from $4.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $14.3 million in Q4 2024 to a low of $3.7 million in Q1 2026.
• Historically, Share-based Compensation has averaged $10.1 million across 5 years, with a median of $11.9 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 60.33% in 2022, then sank 67.93% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $11.6 million in 2022, then rose by 4.4% to $12.2 million in 2023, then gained by 17.6% to $14.3 million in 2024, then tumbled by 67.93% to $4.6 million in 2025, then slipped by 18.67% to $3.7 million in 2026.
• The last three Share-based Compensation figures came in at $3.7 million (Q1 2026), $4.6 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.